Update in tuberculosis and nontuberculous mycobacterial disease 2010

American Journal of Respiratory and Critical Care Medicine

Volumn 184, Issue 2, 2011, Pages 180-185

  Yew, Wing Wai ^a   Sotgiu, Giovanni ^b   Migliori, Giovanni Battista ^c  

^a Hong Kong Tuberculosis Chest and Heart Diseases Association ^*  (Hong Kong)

^b UNIVERSITY OF SASSARI   (Italy)

^c IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFAZIMINE; ETHAMBUTOL; GATIFLOXACIN; ISONIAZID; KANAMYCIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN;

DRUG MEGADOSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LATENT TUBERCULOSIS; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIOSIS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS;

ANIMALS; HUMANS; INTERNATIONALITY; MICE; MYCOBACTERIUM INFECTIONS; TUBERCULOSIS;

EID: 80051562045     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201102-0325UP     Document Type: Review

References (70)

1. World Health Organization. Global tuberculosis control. WHO report 2010. WHO/HTM/TB/2010.7. Geneva, Switzerland: 2010; World Health Organization.
2. LoBue PA, Enarson DA, Thoen TC. Tuberculosis in humans and its epidemiology, diagnosis and treatment in the United States. Int J Tuberc Lung Dis 2010;14:1226-1232.
3. Taiwo B, Glassroth J. Nontuberculous mycobacterial lung diseases. Infect Dis Clin North Am 2010;24:769-789.
4. Mukamolova GV, Turapov O, Malkin J, Woltmann G, Barer MR. Resuscitation-promoting factors reveal an occult population of tubercle bacilli in sputum. Am J Respir Crit Care Med 2010;181:174-180.
5. Kaufmann SH. Future vaccination strategies against tuberculosis: thinking outside the box. Immunity 2010;33:567-577.
6. Chen X, Zhang M, Liao M, Graner MW,Wu C, Yang Q, Liu H, Zhou B. Reduced Th17 response in patients with tuberculosis correlates with IL-6R expression on CD41 T cells. Am J Respir Crit Care Med 2010; 181:734-742.
7. Jeyanathan M, Mu J, McCormick S, Damjanovic D, Small CL, Shaler CR, Kugathasan K, Xing Z. Murine airway luminal antituberculosis memory CD8 T cells by mucosal immunization are maintained via antigen-driven in situ proliferation, independent of peripheral T cell recruitment. Am J Respir Crit Care Med 2010;181:862-872.
8. Tena-Coki NG, Scriba TJ, Peteni N, Eley B, Wilkinson RJ, Andersen P, Hanekom WA, Kampmann B. CD4 and CD8 T-cell responses to mycobacterial antigens in African children. Am J Respir Crit Care Med 2010;182:120-129.
9. Hougardy JM, Schepers K, Place S, Drowart A, Lechevin V, Verscheure V, Debrie AS, Doherty TM, Van Vooren JP, Locht C, et al. Heparinbinding- hemagglutinin-induced IFN-g release as a diagnostic tool for latent tuberculosis. PLoS One 2007;2:e926.
10. Place S, Verscheure V, de San N, Hougardy JM, Schepers K, Dirix V, Dediste A, Michel O, Drowart A, Allard SD, et al. Heparin-binding, hemagglutinin-specific IFN-g synthesis at the site of infection during active tuberculosis in humans. Am J Respir Crit Care Med 2010;182: 848-854.
11. Kagina BM, Abel B, Scriba TJ, Hughes EJ, Keyser A, Soares A, Gamieldien H, Sidibana M, Hatherill M, Gelderbloem S, et al. other members of the South African Tuberculosis Vaccine Initiative. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guerin vaccination of newborns. Am J Respir Crit Care Med 2010;182:1073-1079.
12. Smith SG, Lalor MK, Gorak-Stolinska P, Blitz R, Beveridge NE, Worth A, McShane H, Dockrell HM. Mycobacterium tuberculosis PPD - induced immune biomarkers measurable in vitro following BCG vaccination of UK adolescents by multiplex bead array and intracellular cytokine staining. BMC Immunol 2010;11:35.
13. Moller M, Flachsbart F, Till A, Thye T, Horstmann RD, Meyer CG, Osei I, van Helden PD, Hoal EG, Schreiber S, et al. A functional haplotype in the 39 untranslated region of TNFRSF1B is associated with tuberculosis in two African populations. Am J Respir Crit Care Med 2010;181:388-393.
14. Solovic I, Sester M, Gomez-Reino JJ, Rieder HL, Ehlers S, Milburn HJ, Kampmann B, Hellmich B, Groves R, Schreiber S, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010;36:1185-1206.
15. Horsburgh CR Jr, O'Donnell M, Chamblee S, Moreland JL, Johnson J, Marsh BJ, Narita M, Johnson LS, von Reyn CF. Revisiting rates of reactivation tuberculosis: a population-based approach. Am J Respir Crit Care Med 2010;182:420-425.
16. O'Donnell MR, Chamblee S, von Reyn CF, Ellerbrock TV, Johnson J, Marsh BJ, Moreland JD, Narita M, Pedrosa M, Johnson LS, et al. Racial disparities in primary and reactivation tuberculosis in a rural community in the southeastern United States. Int J Tuberc Lung Dis 2010;14:733-740.
17. Erkens CG, Kamphorst M, Abubakar I, Bothamley GH, Chemtob D, Haas W, Migliori GB, Rieder HL, Zellweger JP, Lange C. Tuberculosis contact investigation in low prevalence countries: a European consensus. Eur Respir J 2010;36:925-949.
18. Hirsch-Moverman Y, Bethel J, Colson PW, Franks J, El-Sadr W. Predictors of latent tuberculosis infection treatment completion in the United States: an inner city experience. Int J Tuberc Lung Dis 2010; 14:1104-1111.
19. Mack U, Migliori GB, Sester M, Rieder HL, Ehlers S, Goletti D, Bossink A, Magdorf K, Hölscher C, Kampmann B, et al. TBNET. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J 2009;33: 956-973.
20. Arshad S, Bavan L, Gajari K, Paget SN, Baussano I. Active screening at entry for tuberculosis among new immigrants: a systematic review and meta-analysis. Eur Respir J 2010;35:1336-1345.
21. Kik SV, Franken WP, Mensen M, Cobelens FG, Kamphorst M, Arend SM, Erkens C, Gebhard A, Borgdorff MW, Verver S. Predictive value for progression to tuberculosis by IGRA and TST in immigrant contacts. Eur Respir J 2010;35:1346-1353.
22. Mor Z, Lerman Y, Leventhal A. Pre-immigration screening for pulmonary tuberculosis. Eur Respir J 2009;33:701-702.
23. Klinkenberg E, Manissero D, Semenza JC, Verver S. Migrant tuberculosis screening in the EU/EEA: yield, coverage and limitations. Eur Respir J 2009;34:1180-1189.
24. Middelkoop K, Bekker LG, Myer L, Whitelaw A, Grant A, Kaplan G, McIntyre J, Wood R. Antiretroviral program associated with reduction in untreated prevalent tuberculosis in a South African township. Am J Respir Crit Care Med 2010;182:1080-1085.
25. World Health Organization. Treatment of tuberculosis: Guidelines, 4th ed. WHO/HTM/TB2009.420. Geneva, Switzerland: 2010; World Health Organization.
26. Gandhi NR, Shah NS, Andrews JR, Vella V, Moll AP, Scott M, Weissman D, Marra C, Lalloo UG, Friedland GH; Tugela Ferry Care and Research (TFCARES) Collaboration. HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med 2010;181:80-86.
27. King L, Munsiff SS, Ahuja SD. Achieving international targets for tuberculosis treatment success among HIV-positive patients in New York City. Int J Tuberc Lung Dis 2010;14:1613-1620.
28. Dheda K, Shean K, Zumla A, Badri M, Streicher EM, Page-Shipp L, Willcox P, John MA, Reubenson G, Govindasamy D, et al. Early treatment outcomes and HIV status of patients with extensively drugresistant tuberculosis in South Africa: a retrospective cohort study. Lancet 2010;375:1798-1807.
29. Migliori GB, Sotgiu G. XDR tuberculosis in South Africa: old questions, new answers. Lancet 2010;375:1760-1761.
30. Shin SS, Keshavjee S, Gelmanova IY, Atwood S, Franke MF, Mishustin SP, Strelis AK, Andreev YG, Pasechnikov AD, Bamashov A, et al. Development of extensively drug-resistant tuberculosis during multidrug-resistant tuberculosis treatment. Am J Respir Crit Care Med 2010;182: 426-432.
31. Kim DH, Kim HJ, Park SK, Kong SJ, Kim YS, Kim TH, Kim EK, Lee KM, Lee SS, Park JS, et al. Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010;182:113-119.
32. Migliori GB, Besozzi G, Girardi E, Kliiman K, Lange C, Toungoussova OS, Ferrara G, Cirillo DM, Gori A, Matteelli A, et al. SMIRA/ TBNET Study Group. Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur Respir J 2007;30:623-626. (Pubitemid 351194820)
33. Sotgiu G, Ferrara G, Matteelli A, Richardson MD, Centis R, Ruesch- Gerdes S, Toungoussova O, Zellweger JP, Spanevello A, Cirillo D, et al Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur Respir J 2009;33:871-881.
34. Migliori GB, Richardson MD, Lange C. Of blind men and elephants: making sense of extensively drug-resistant tuberculosis. Am J Respir Crit Care Med 2008;178:1000-1001.
35. Baussano I, Nunn P, Williams B, Pivetta E, Bugiani M, Scano F. Tuberculosis among health care workers. Emerg Infect Dis 2011;17: 488-494.
36. O'Donnell MR, Jarand J, Loveday M, Padavatchi N, Zelnick J, Weiner L, Naidoo K, Master I, Osburn G, Kvasnovsky C, et al High incidence of hospital admissions with multidrug-resistant and extensively drugresistant tuberculosis among South African health care workers. Ann Intern Med 2010;153:516-522.
37. van Zyl Smit RN, Pai M, Yew WW, Leung CC, Zumla A, Bateman ED, Dheda K. Global lung health: the colliding epidemics of tuberculosis, tobacco smoking, HIV and COPD. Eur Respir J 2010;35:27-33.
38. Slama K, Chiang CY, Hinderaker SG, Bruce N, Vedal S, Enarson DA. Indoor solid fuel combustion and tuberculosis: is there an association? Int J Tuberc Lung Dis 2010;14:6-14.
39. Kim SH, Choi SJ, Kim HB, Kim NJ, Oh MD, Choe KW. Diagnostic usefulness of a T-cell based assay for extrapulmonary tuberculosis. Arch Intern Med 2007;167:2255-2259.
40. Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K; IGRA Expert Committee; Centers for Disease Control and Prevention (CDC). Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosisinfection - United States, 2010.MMWR Recomm Rep 2010;59:1-25.
41. Patel VB, Singh R, Connolly C, Coovadia Y, Peer AK, Parag P, Kasprowicz V, Zumla A, Ndung'u T, Dheda K. Cerebrospinal T-cell responses aid in the diagnosis of tuberculous meningitis in a human immunodeficiency virus- and tuberculosis-endemic population. Am J Respir Crit Care Med 2010;182:569-577.
42. Metcalfe JZ, Cattamanchi A, Vittinghoff E, Ho C, Grinsdale J, Hopewell PC, Kawamura LM, Nahid P. Evaluation of quantitative IFN-g response for risk stratification of active tuberculosis suspects. Am J Respir Crit Care Med 2010;181:87-93.
43. Leung CC, Yam WC, Yew WW, Ho PL, Tam CM, Law WS, Au KF, Tsui PW. T-SPOT.TB outperforms tuberculin skin test in predicting tuberculosis disease. Am J Respir Crit Care Med 2010;182:834-840.
44. World Health Organization. Strategic and Technical Advisory Group for Tuberculosis (STAG-TB), Report of the Tenth Meeting, September 27-29, 2010. WHO/HTM/TB/2010.18. Geneva, Switzerland: 2010; World Health Organization.
45. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, Allen J, Tahirli R, Blakemore R, Rustomjee R, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363:1005-1015.
46. Swaminathan S, Narendran G, Venkatesan P, Iliayas S, Santhanakrishnan R, Menon PA, Padmapriyadarsini C, Ramachandran R, Chinnaiyan P, Suhadev M, et al. Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial. Am J Respir Crit Care Med 2010;181: 743-751.
47. Vernon A. A trial involving HIV-tuberculosis in India: the minute particulars. Am J Respir Crit Care Med 2010;181:652-654.
48. Yew WW, Lange C, Leung CC. Treatment of tuberculosis: update 2010. Eur Respir J 2011;37:441-462.
49. Chiang CY, Schaaf HS. Management of drug-resistant tuberculosis. Int J Tuberc Lung Dis 2010;14:672-682.
50. Caminero JA. Multidrug-resistant tuberculosis: epidemiology, risk factors and case finding. Int J Tuberc Lung Dis 2010;14:382-390.
51. Caminero JA, Sotgiu G, Zumla A, Migliori GB. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010;10:621-629.
52. Leimane V, Dravniece G, Riekstina V, Sture I, Kammerer S, Chen P, Skenders G, Holtz TH. Treatment outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000-2004. Eur Respir J 2010;36: 584-593.
53. Migliori GB, Eker B, Richardson MD, Sotgiu G, Zellweger JP, Skrahina A, Ortmann J, Girardi E, Hoffmann H, Besozzi G, et al. TBNET Study Group. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in MDR-TB. Eur Respir J 2009;34:387-393.
54. Yew WW, Chang KC, Chau CH. What is the optimal dosage of linezolid in treatment of complicated multidrug-resistant tuberculosis. Eur Respir J 2009;34:1492-1494.
55. Anger HA, Dworkin F, Sharma S, Munsiff SS, Nilsen DM, Ahuja SD. Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-06. J Antimicrob Chemother 2010;65:775-783.
56. Schecter GF, Scott C, True L, Raftery A, Flood J, Mase S. Linezolid in the treatment of multidrug-resistant tuberculosis. Clin Infect Dis 2010; 50:49-55.
57. Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, Daru P, Rieder HL. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010;182:684-692.
58. Mitnick C, Horsburgh CR Jr. Encouraging news for multidrug-resistant tuberculosis treatment. Am J Respir Crit Care Med 2010;182:1337-1338.
59. Chang KC, Leung CC, Yew WW, Lau TY, Leung WM, Tam CM, Lam HC, Tse PS, Wong MY, Lee SW, et al. Newer fluoroquinolones for treating respiratory infection: do they mask tuberculosis? Eur Respir J 2010;35:606-613.
60. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2008.402. Geneva, Switzerland: 2008; World Health Organization.
61. Oxlade O, Schwartzman K, Pai M, Heymann J, Benedetti A, Royce S, Menzies D. Predicting outcomes and drug resistance with standardised treatment of active tuberculosis. Eur Respir J 2010;36:870-877.
62. Nunn A. What is the role of clinical trials for the treatment of tuberculosis and what are the alternatives? Int J Tuberc Lung Dis 2010;14: 380-381.
63. Lienhardt C, Davies G. Methodological issues in the design of clinical trials for the treatment of multidrug-resistant tuberculosis: challenges and opportunities. Int J Tuberc Lung Dis 2010;14:528-537.
64. Tedla Z, Nyirenda S, Peeler C, Agizew T, Sibanda T, Motsamai O, Vernon A, Wells CD, Samandari T. Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in HIV-infected adults in Botswana. Am J Respir Crit Care Med 2010;182:278-285.
65. Abel B, Tameris M, Mansoor N, Gelderbloem S, Hughes J, Abrahams D, Makhethe L, Erasmus M, de Kock M, van der Merwe L, et al. The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD41 and CD81 T cells in adults. Am J Respir Crit Care Med 2010;181:1407-1417.
66. Sada-Ovalle I, SkoldM, Tian T, Besra GS, Behar SM. a-Galactosylceramide as a therapeutic agent for pulmonary Mycobacterium tuberculosis infection. Am J Respir Crit Care Med 2010;182:841-847.
67. Andrejak C, Thomsen VO, Johansen IS, Riis A, Benfield TL, Duhaut P, Sorensen HT, Lescure FX, Thomsen RW. Nontuberculous pulmonary mycobacteriosis in Denmark: incidence and prognostic factors. Am J Respir Crit Care Med 2010;181:514-521.
68. Winthrop KL, McNelley E, Kendall B, Marshall-Olson A, Morris C, Cassidy M, Saulson A, Hedberg K. Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease. Am J Respir Crit Care Med 2010;182:977-982.
69. Prevots DR, Shaw PA, Strickland D, Jackson LA, Raebel MA, Blosky MA, Montes de Oca R, Shea YR, Seitz AE, Holland SM, et al. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med 2010;182:970-976.
70. Montes-Worboys A, Brown S, Regev D, Bellew BF, Mohammed KA, Faruqi I, Sharma P, Moudgil B, Antony VB. Targeted delivery of amikacin into granulomas. Am J Respir Crit Care Med 2010;182:1546-1553.